Momentus

Phase A — Understand the business

Company Overview

Momentus is a "commercial space infrastructure" company. Per its own framing, it offers (or plans to offer — the hedging is constant) five product lines:

1. Space transportation — a "hub-and-spoke" model: ride-share the customer's satellite to a drop-off orbit on a partner rocket (primarily SpaceX), then use a Momentus Orbital Service Vehicle (OSV) — the Vigoride — to tug the payload "last mile" to a precise custom orbit.
2. Hosted payloads — bolt a customer's instrument onto a Momentus bus that shares power/comms; the customer tests a capability in orbit without buying a whole satellite. This is what actually generated 2025–26 revenue.
3. Satellite buses / constellation buses — high-volume production of low-cost buses (M-500, M-1000 variants introduced Aug 2023) sold as a traditional prime contractor.
4. Satellite components — the TASSA solar array, 3D-printed propulsion tanks, MET thrusters.
5. In-orbit servicing (future) — inspection, refueling, life-extension, de-orbit, debris removal. Aspirational; requires Rendezvous & Proximity Operations (RPORemaining performance obligationsRevenue a company has already signed contracts for but has not yet delivered or booked.) the company is only now demonstrating.

Core technology. The MET uses water as propellant — non-toxic, easy to handle, high specific impulse — and Momentus claims TRL-9 ("hundreds of successful firings in space"). The TASSA is a deployable/retractable solar array pitched as substantially cheaper than competitors. IP estate as of 12/31/25: eight U.S. issued patents, four non-U.S. issued, one additional application family — a thin portfolio.

Customers. Government and commercial satellite operators. In practice the 2025–26 revenue is overwhelmingly U.S. government / defense-adjacent: NASA, DARPA, AFRL, the U.S. Space Force's SpaceWERX (which awarded a Direct-to-Phase-II SBIR for an RPO sensor suite), plus commercial names flying on Vigoride 7 (Orbit Fab, Portal Space Systems, CisLunar Industries, DPhi Space, Solstar). The our figures on disk is empty — no per-customer revenue concentration is compiled, so concentration below is inferred from disclosure.

Contract structure. Hosted-payload and engineering-services contracts, recognized over time as performance obligations are satisfied. No take-or-pay, no recurring SaaS-like base — revenue is project-lumpy (the 10x YoY Q1 swing, $0.3M → $3.2M, proves it). Backlog is not quantified anywhere in the 10-K beyond risk-factor boilerplate about "converting backlog or inbound inquiries into revenue" — a tell that backlog is immaterial or undisclosed.

Bottom line: a pre-commercial space-logistics option with one genuinely-differentiated subsystem (water-plasma propulsion), monetized today as a government hosted-payload integrator, wrapped in a much larger "someday in-orbit servicing" story.

Supply Chain

The commercial-layer supply-chain.md for the space topic is missing (the briefing flags it), so this is mapped from the 10-K + web. Named stakeholders along the chain:

Upstream (inputs into Momentus):

• Launch providers (the critical dependency): Momentus does not launch — it buys ride-share. Named relationships: SpaceX (primary; Vigoride 7 flew on Transporter-16), Relativity Space, Blue Origin, United Launch Alliance (ULA), Rocket Factory Augsburg (RFA). SpaceX Transporter ride-share is the single most important supplier — pricing, cadence, and manifest slots are all SpaceX-controlled.
• Additive manufacturing: Velo3D — strategic partner producing a 3D-printed metal fuel tank flight-tested on Vigoride 7. Note Velo3D is itself a distressed post-SPAC additive-manufacturing name (recently raised ~$30M) — a fragile supplier.
• Components / raw materials: the 10-K explicitly warns Momentus relies "on a limited number of suppliers for certain raw materials, specialized labor, and supplied components" — i.e. single-source exposure on inputs, unquantified.
• Specialized labor with security clearances — a named constraint given the defense customer mix.

Momentus (the integrator): designs/builds the Vigoride OSV and buses in San Jose (1762 Automation Parkway), integrates customer payloads, obtains FCC/export licenses, operates the vehicle on orbit.

Downstream (end customers): U.S. government (NASA, DARPA, AFRL, SpaceWERX) + commercial satellite operators / space-tech startups (Orbit Fab, Portal Space, CisLunar, DPhi, Solstar).

Chokepoints / single-source dependencies:

• Launch access = the master chokepoint. No SpaceX slot, no mission. Momentus is a price-taker on the most important line of its cost stack (cost of revenue is "primarily third-party launch costs").
• Capital is the real upstream input. The genuine "supply chain" here is the equity market: every mission is funded by a fresh stock issuance (Lens 5/9). The supplier of last resort is AGP's ATM desk.
• Regulatory licensing (FCC, export/ITAR) is a non-negotiable gate on every mission.

This lens is thin by necessity — Momentus is small enough that its "supply chain" is mostly "buy a SpaceX seat, integrate in-house, get a license."

Competitive Advantages (moats)

Claimed moats: (1) modular common technology across vehicles; (2) patent-pending water-plasma propulsion; (3) launch-provider compatibility/relationships; (4) an experienced management team (ex-DoD, Raytheon, Lockheed, Maxar, ULA, Northrop).

Honest assessment — the moat is shallow-to-nonexistent at current scale:

• Water-plasma propulsion (MET) is the one defensible differentiator — non-toxic propellant, demonstrated on orbit, eight issued patents. But electric/chemical propulsion is a crowded field, and the company itself says it can swap in third-party chemical/electric thrusters, undercutting the "our thruster is the moat" story.
• Switching costs: low. Hosted-payload and last-mile tug services are substitutable. A customer can fly the same payload on D-Orbit's ION, Impulse Space's Mira, Exolaunch, or Spaceflight, or simply buy a dedicated SpaceX rideshare slot.
• Network effects: none. Brand: negative — the SPAC-fraud heritage is a reputational liability with exactly the government customers it needs (Lens 10).
• Scale: anti-moat. At $1–10M revenue and 35 employees, Momentus is sub-scale against vertically-integrated, well-funded rivals.
• Bargaining power: weak both ways. It needs SpaceX more than SpaceX needs it; it needs each customer more than the customer needs it (it is one of many tug/host options).

The only real edge is credibility-as-a-defense-vendor — John Rood's national-security résumé reopened the U.S.-government door that founder Kokorich's CFIUS problem had slammed shut. That is a relationship/clearance moat, not a technology moat, and it is personal to Rood.

Segments

our figures is empty — Momentus does not report multiple segments. It operates as a single reportable segment reviewed by the CEO as chief operating decision-maker. All revenue is "Service revenue."

By the only available cut — period and (inferred) end-market:

Trend & cause. FY2025 revenue fell 47% as the Vigoride 5/6 performance obligations wound down. Then Q1 2026 exploded to $3.2M — more than all of FY2025 in a single quarter — driven by the Vigoride 7 hosted-payload mission and government engineering-services work. Management now guides ~$10M FY2026 revenue. Geographic split is not disclosed; the de-facto concentration is U.S. government. The takeaway: revenue is mission-gated and binary — it spikes when a Vigoride flies and collapses between missions. There is no smooth segment trend to extrapolate; there is a launch calendar.

---

Phase B — Measure performance

Earnings Result

FY2025 income statement:

Q1 2026: Service revenue $3,215K (vs $322K), cost of revenue $1,398K, R&D $4,169K, SG&A $6,340K, total opex $10,509K, loss from operations $(8,692)K, net loss $(9,480)K (vs $(6,172)K — loss widened YoY despite the revenue jump, because opex scaled with the Vigoride 7 campaign).

Read-through:

• Revenue is de minimis relative to the cost base. FY2025 generated $1.1M of revenue while spending $28.4M to operate — a ~25:1 burn-to-revenue ratio. The cost structure is essentially fixed R&D + SG&A for a company with almost no commercial output.
• Cost of revenue near-zero in FY25 ($2K) means the trivial revenue carried ~100% gross margin — but that is an artifact of recognizing residual obligations, not a margin story. Q1 2026 cost of revenue ($1,398K on $3,215K revenue, ~57% gross margin) is more representative once a real mission is flying.
• The losses are shrinking only because the company is shrinking (headcount cuts, restructurings), not because it is scaling toward profitability.

Balance sheet (12/31/25): Total assets $40.3M (up sharply from $9.95M a year earlier — financing-driven: cash + a $9.3M "prepaids/other current assets" line that includes prepaid launch/services, + $11.3M restricted cash), total liabilities $23.2M, stockholders' equity swung to +$17.1M from a $(7.8)M deficit — entirely because of equity raises, not earnings.

Cash flow: Net cash used in operating activities $(23.3)M in FY2025 (vs $(16.6)M FY2024) — burn accelerated by ~40%. Against year-end cash of $12.8M, that is roughly half a year of runwayRunwayHow long the cash lasts at the current rate of spending. It shortens the moment spending rises, which is why a figure taken from a quiet quarter flatters. absent new financing — which is exactly why the going-concern flag was raised.

Guidance & tone change. The pivotal disclosure shift: the 10-K (March 2026) carried explicit going-concern / substantial-doubt language; the Q1 10-QForm 10-QThe quarterly version of the annual report. Lighter, and not audited. (May 2026) states "substantial doubt no longer exists" after ~$84.6M of post-year-end raises lifted cash to ~$76M. Tone flipped from survival to "executing long-term growth strategy."

Market reaction: violent. MNTS ran from a $4.57 close (May 1) to $13.85 (May 26), +200%+, on the Q1 print + going-concern removal + SpaceX-IPO-halo, then bled back toward ~$7.30 by June 29. This is squeeze-and-fade behavior, not fundamental re-rating.

Earnings Calls (sentiment trend)

transcripts/ is empty (none ingested; the small-cap calls are not on Fool/Insider-Monkey). Sentiment is reconstructed from filings + press releases, so treat the trend as -derived.

Trajectory of management messaging over the last ~4 quarters:

• Mid-2025: existential. Repeated reverse-split announcements, Nasdaq deficiency letters, going-concern emphasis. Theme: survival and compliance.
• Late 2025 (Dec): the 1-for-17.85 reverse splitReverse stock splitMerging several shares into one to lift the share price. It changes nothing about what the company is worth, and is usually done to keep a listing or to prepare a larger raise. — framed as "making the bid price attractive to institutional investors," but the market read it as a desperation move (shares fell on the announcement).
• Early 2026 (Jan–Mar): pivot to mission narrative — Velo3D 3D-printed tank, Vigoride 7 prep, 10 hosted payloads, SpaceWERX RPO award. Theme: we have real technology and real government customers.
• Q1 2026 (Apr–Jun): triumphal — "strengthened balance sheet, $76M cash, debt-free," "going-concern doubt removed," "~$10M revenue guide," Vigoride 8 fully subscribed for NASA in 2027. Theme: turnaround / long-term growth.

Recurring phrases: "in-space infrastructure services," "modular vehicles," "water plasma propulsion," "flight heritage," "fully subscribed." What they stopped saying: the going-concern caveat (dropped in May 2026) and the reverse-split/compliance language (resolved). The sentiment arc is genuinely improving — but it tracks the financing window and one successful deployment, not durable commercial traction. The risk is that the same arc has played before (post-2021 it was also "real technology, real customers") and ended in two reverse splits.

Comps

Momentus is nearly un-comparable on multiples — it has almost no revenue, so EV/Sales is meaningless-to-absurd and there are no earnings for P/E. Multiples below are; where a clean figure isn't sourceable it is marked n/a. ROE for a company with a $438.6M accumulated deficit and equity that only just turned positive is not meaningful (n/m).

What the table says: the credible public space-infrastructure names trade on hundreds of millions of revenue (Redwire ~5.7x sales; Rocket Lab ~73x sales on a growth premium). Momentus has ~$10M of guided revenue and a market capMarket capitalisationThe share price multiplied by the number of shares. What the market says the equity is worth. that is a rounding error and a function of float-squeeze mechanics, not fundamentals. On its FY2025 actual $1.1M, the ~$42M cap is ~38x trailing sales for a shrinking, loss-making, serially-diluting micro-cap. There is no multiple at which this is "cheap"; it is an option on execution, priced by sentiment.

Stock-Price Catalysts

What has moved MNTS >5% over its public life:

• 2021-07 — SEC fraud charges + $7M settlement (founding event; permanent reputational scar). Down.
• 2022 — Vigoride 3 inaugural mission anomalies (solar-array deployment problems, couldn't complete tech demos). Down.
• 2023–2025 — serial dilution & Nasdaq compliance saga — deficiency letters, two reverse splits (1-for-14, then 1-for-17.85 effective Dec 17, 2025), repeated ATM/PIPE raises. Each issuance announcement = a leg down (e.g. −27% on a $25M offering; −16% premarket on a registered direct).
• 2026-01 — Velo3D partnership / Vigoride 7 prep. Up.
• 2026-04 — Vigoride 7 deployment off Transporter-16. Up.
• 2026-05 — Q1 print ($3.2M rev) + going-concern removal. +200%+ squeeze ($4.57 → $13.85).
• 2026-Q2 — SpaceX $1.75T IPO halo lifting the entire space complex; MNTS +145% YTD at one point.
• 2026-06 — new $75M ATM filing. Down (dilution).

Pattern: MNTS reacts to exactly two things — (1) dilution events (always down) and (2) narrative/mission/macro-halo events (sharp, short-lived squeezes up). It does not re-rate on fundamentals because there are none to anchor to. This is a catalyst-and-float trading vehicle: low share count post-split (5.7M → ~10M and climbing), high retail interest, SpaceX-IPO beta. The tape rewards momentum and punishes the inevitable next raise.

---

Phase C — Judge people & books

Management

CEO / President / Chairman: John C. Rood (since Aug 2021). The defining fact about Momentus's management is that Rood was installed as the fix for the fraud. Background:

• Under Secretary of Defense for Policy (2018–Feb 2020) — principal policy advisor to the SecDef. (Notably, asked to resign by President Trump in Feb 2020.)
• SVP Lockheed Martin International (2016–2018); VP US Business Development at Raytheon (2009–2014); senior State Dept / NSC / CIA roles.
• Track record: a career national-security-policy and defense-BD executive, not an operator who has built and scaled a hardware company to profitability. His quantified Momentus deliverable is modest: took the company public, launched its first OSVs, "placed eight customer satellites in orbit." He has not delivered profitability, scale, or a stable share price.

Why he matters: Rood's clearances and DoD relationships are the asset. Founder Mikhail Kokorich (Russian-born) was a CFIUS national-security problem that blocked the licenses Momentus needs; the SEC found Momentus misrepresented how badly that undermined its licensing. Rood is the American defense insider who made Momentus fundable by U.S. government customers again. CFO: Lon Ensler.

Skin in the game / insider ownership: thin. The 10-K shows the meaningful equity holders are the financing counterparties — serial warrant investors (March/Aug/Oct/Dec 2025 warrant tranches, each with 9.99% beneficial-ownership blockers) and entities like "SIV" (Space Infrastructures Ventures) — i.e. the cap table is dominated by dilutive financiers, not aligned founder/insider stakes. After two reverse splits and constant issuance, original insider stakes are heavily diluted.

Capital-allocation history: value-destructive by necessity. $438.6M of cumulative losses funded almost entirely by equity; two reverse splits; ROE/ROIC deeply negative throughout. Management's "capital allocation" is serial dilution — there is no buyback, no acquisition discipline, no FCFFree cash flowCash left after paying to run and maintain the business. Unlike profit, it is hard to flatter with accounting choices. to allocate. To their credit, the company is now debt-free with ~$76M cash, and they have repeatedly avoided delisting and bankruptcy — survival itself is a (low-bar) achievement.

Founder vs. professional manager: decisively professional/turnaround manager (the founder was forced out). Implication: Momentus is run by a credentialed fixer optimizing for survival, government access, and narrative — appropriate for its stage, but it means the company lacks a technical founder-visionary driving the product, and the CEO's edge (DoD relationships) is personal and non-transferable.

Red flags: the entire founding fraud (Lens 10); pay-vendors/settle-disputes-in-stock behavior (e.g. issuing 5,723 shares to a vendor in March 2026 to settle payables ); a cap table built on toxic-adjacent warrant financing.

Forensic Red Flags

Accounting-statement risks:

• Going-concern whiplash (the #1 flag). The 10-K (Mar 2026) disclosed substantial doubt; the 10-Q (May 2026) removed it after post-quarter raises. The doubt was removed by financing, not by operations — burn is still ~$23M/yr against ~$10M of guided revenue, so the going-concern question will recur the moment the cash window closes. Treat "doubt removed" as a temporary, financing-dependent state.
• Revenue recognition / lumpiness. Service revenue swings 10x quarter-to-quarter ($0.3M → $3.2M) on mission timing and over-time performance-obligation recognition. Tiny absolute numbers make any single contract's timing material to the trend — easy to flatter a quarter.
• Equity-classified vs. liability-classified instruments — fair-value noise. The ELOC pre-funded warrants are liability-classified, Level 3 fair-valued. Changes in fair value of derivatives/warrants flow through the P&L and can distort "other income/expense" and the bottom line independent of operations. With many warrant tranches outstanding (2,096,947 warrants in one block alone, plus numerous smaller tranches), mark-to-market swings are a recurring non-operating distortion.
• Stock-based comp & stock-for-payables flatter cash burnCash burnHow much more cash goes out than comes in, per period. The clock on a company with no profits. vs. GAAP loss; paying vendors in shares (Mar 2026) shifts cost off the cash statement onto dilution.
• Restricted cash $11.3M is a large share of the balance sheet — encumbered, not freely available; the "$76M cash" headline should be read net of restrictions.
• Material weakness: a prior material weakness (misclassification errors) was disclosed and management states it has been remediated and ICFR is now effective. Worth monitoring given a small finance team and a small auditor (Frank, Rimerman + Co. LLP, San Francisco — a regional firm, not a Big Four).

Regulatory findings (required sub-section):

• SEC EDGAR EFTS (LR + AAER): regulatory/regulatory-findings.md reports 0 Litigation Releases and 0 AAERs naming Momentus in 2021-06-30 → 2026-06-30. However, this understates reality: the landmark action was an administrative cease-and-desist settlement, not an LR/AAER, so it does not appear in those two indices.
• The founding fraud (the central red flag): The SEC charged the Stable Road SPAC, its sponsor (SRC-NI), its CEO Brian Kabot, Momentus, and founder Mikhail Kokorich for misleading disclosures. Findings: Momentus repeatedly told investors it had "successfully tested" its propulsion technology in space when its only in-space test had FAILED to achieve its primary objectives; and it misrepresented the national-security (CFIUS) concerns around Kokorich that undermined its ability to get licenses. Settlement (no admit/deny): Momentus paid $7M, Stable Road $1M, Kabot $40,000; sponsor forfeited founder shares; investor-protection undertakings imposed. SEC litigation continued against Kokorich in D.D.C. This is the most important single fact in the dossier: the company's origin story was a securities fraud about the very technology and government-access that are its thesis.
• Civil litigation (Item 3 + notes): Multiple shareholder derivative actions (Lindsey, Rivlin, Hanna; "Derivative Action II" names CEO John Rood) echoing the Securities Class Actions; the Securities Class Action was settled and paid in full; an ongoing insurance-coverage dispute with ANV (the Side-A D&O insurer) — agreed in principle April 2026 to settle for ~$1M. Item 3 itself states management does not consider pending proceedings, individually or in aggregate, currently likely to be material — but the litigation tail is entirely fraud-derived.
• Non-SEC agencies (web search): No material FTC/DOJ/FDA/CFPB enforcement found. Export-control/ITAR compliance is an ongoing risk (heavily flagged in risk factors) but no enforcement action is on record.
• Net: SEC EDGAR LR/AAER clean, but a defining 2021 SEC fraud settlement ($7M) + a heavy fraud-derived civil-litigation tail. Verified via SEC EDGAR EFTS (LR, AAER), SEC press release 2021-124, web search, and 10-K Item 3 as of 2026-06-30.

---

Phase D — Project & stress-test

Forward Projection

Momentus does not give multi-year EPS guidance; it guides only ~$10M FY2026 revenue. EPS is deeply negative and dominated by a moving, diluting share count (5.73M shares at the 10-K → ~9.99M by mid-May → climbing as the $75M ATM is used). Projecting EPS three years out for a pre-commercial serial-diluter is low-confidence by construction; I give a directional range and explicitly refuse to manufacture false precision. No our model logged (unattended --watchlist; no committed base case — this is a watch, not a conviction position).

Inputs:

• Revenue: FY2026 ~$10M (mgmt guide); FY2027 ~$15–25M if Vigoride 8 (NASA, fully subscribed, 2027) flies and 1–2 new missions convert; FY2028 highly path-dependent — could be $25–50M if servicing/bus contracts scale, or flat-to-down if missions slip.
• Opex: roughly fixed ~$30–40M/yr R&D+SG&A, scaling with mission cadence.
• Net loss: ~$25–35M/yr continuing for the foreseeable future; positive operating income is not in view on a 3-year horizon without a step-change in contract scale.
• Shares: diluting materially every year via ATM/PIPE/warrants — the per-share denominator is a headwind that swamps any modeling.

Three-year EPS path:

• Bear: missions slip / a Vigoride fails / revenue stalls near $5–10M; continued $25–30M losses; heavy dilution → another reverse split possible. EPS deeply negative; equity → near-zero.
• Base: revenue $10M (FY26) → ~$18M (FY27) → ~$30M (FY28); losses persist ~$25–30M/yr; share count up 30–50%/yr. Still loss-making in FY28; EPS negative throughout.
• Bull: Vigoride 7/8 RPO+servicing demos succeed → larger DoD/NASA servicing and bus contracts → revenue $10M → $30M → $60M+; losses narrow toward breakeven by ~FY29; the SpaceX-IPO halo sustains a financing premium so dilution is "cheap." Even here, GAAP profitability is beyond the 3-year window.

The honest projection: there is no credible path to positive EPS within three fiscal years. The investable question is not "what's the EPS" — it's "does the cash runway (~$76M, mid-2026) reach enough revenue-generating missions to keep the equity window open without a value-destroying down-round or another reverse split?" At ~$23M/yr operating burn, $76M is ~3 years of runway if burn doesn't rise — but burn rises with mission cadence, and the $75M ATM signals management expects to keep tapping the market.

Bull vs Bear

Bull case. Momentus is a cheap (~$42M) call option on three converging tailwinds: (1) a structurally growing space-logistics/in-orbit-servicing market (autonomous space-tug market ~$1.8B in 2026 → ~$3.3B by 2030 at ~16.6% CAGR; orbital-transfer tug forecasts as high as ~$7.9B by 2033 ); (2) genuinely differentiated, flight-proven water-plasma propulsion and a credible DoD/NASA customer roster (SpaceWERX RPO award, NASA Space Act Agreement, Vigoride 8 NASA-subscribed); (3) a defense-credentialed CEO who reopened the government channel. With going-concern doubt removed, ~$76M cash, debt-free, and Vigoride 7 flying 10 real payloads, the survival overhang has lifted — and in a SpaceX-$1.75T-IPO-halo environment, a sub-scale name with real hardware and a low float can re-rate violently (it already ran +200% on the Q1 print). If the RPO/servicing demos succeed, Momentus becomes an acquisition target or a genuine niche servicing prime.

Bear case (the structural reality — 2–3 permanent-impairment risks):

1. The economics don't work and may never. $1.1M revenue / $28M opex / $30.5M loss / $438.6M accumulated deficit. The model has been "almost commercial" for five years and produced two reverse splits. Sub-scale against vertically-integrated, better-funded rivals (Impulse, D-Orbit, Astroscale, Rocket Lab), with no moat, low switching costs, and a negative brand.
2. Perpetual dilution is the business model. Every mission is equity-funded; the share count compounds (5.7M → 10M+ in two months) and a fresh $75M ATM is loaded. Equity holders are diluted continuously; the stock falls on every raise. This is mathematically hostile to long-term holders.
3. Mission/technology failure risk is existential. One Vigoride loss (and Vigoride 3 already under-delivered) destroys the narrative and the financing window simultaneously. A 35-person company has no margin for a failed mission.

Pre-mortem (18 months out, thesis broke): Vigoride 7's RPO/servicing demos disappointed or a subsequent mission failed; the SpaceX-IPO halo faded and the space-momentum trade reversed; the $75M ATM got used at progressively lower prices, the stock slid back below $1 post-dilution, and a third reverse split was announced — going-concern doubt returned. The squeeze-buyers from May 2026 were the exit liquidity.

Are multiples too high? There is no multiple — it's an option priced on sentiment. At ~38x trailing actual sales (and only ~4x on a guided number management has every incentive to hit-or-miss), it is expensive for what it is: a pre-commercial, cash-burning micro-cap. The market is pricing optionality + squeeze mechanics, not cash flows.

Contrarian view (what the market refuses to see): Bulls see "debt-free, $76M cash, going-concern removed, revenue +900%, SpaceX halo" and price a turnaround. The contrarian read: the going-concern removal is the tell, not the all-clear — it was bought with $84.6M of dilution at squeeze-inflated prices, which is precisely how this management funds a structurally-unprofitable business between narrative spikes. The +900% revenue is $0.3M → $3.2M — a single mission, not a trend. The most dangerous thing for new shareholders is that the company is now well-capitalized enough to keep diluting them for two more years without the discipline of an imminent bankruptcy.

Devil's Advocate (short-seller)

Dismantling the bull case:

• What structurally breaks the money-making? It was never built. Five years post-SPAC, peak annual revenue is ~$2M and falling; the "commercial" model is a government hosted-payload integrator with ~$10M of hoped-for revenue against ~$30M of cost. There is no operating leverage in sight.
• Revenue concentration: effectively U.S. government + a handful of small commercial payloads, recognized lumpily on mission timing. Lose or slip one mission and revenue halves. SpaceWERX/NASA budget priorities (and DoD program risk, explicitly flagged) can cut it off.
• Why the moat is weaker than bulls think: water-plasma propulsion is nice but swappable (the company itself offers chemical/electric alternatives); hosted-payload and last-mile tug are commoditized services with multiple substitutes; brand is a liability with the exact government buyers it courts.
• Most dangerous competitor bulls underestimate: Impulse Space — founded by SpaceX's Tom Mueller, far better funded, building Mira (LEO) and Helios (high-energy) tugs; it can out-capitalize and out-engineer Momentus on the same missions. Plus D-Orbit (real commercial last-mile heritage) and Astroscale (the servicing/RPO leader). Momentus is the smallest, weakest-balance-sheet player in a field about to consolidate.
• Worst capital-allocation / governance: the founding securities fraud (Momentus paid $7M; founder charged); a cap table built on toxic-adjacent warrant/ELOC financing with 9.99% blockers; paying vendors and settling disputes in stock; two reverse splits in a year. Incentives are oriented around survival-via-issuance, which is misaligned with buy-and-hold shareholders.
• What must hold for today's price? That the SpaceX-IPO halo + low float keep a squeeze premium alive, and that Vigoride 7/8 succeed, and that dilution stays "cheap." Three fragile conditions.
• If growth disappoints 20–30%: there's barely any growth to disappoint — but a missed $10M guide (very plausible given lumpiness) or a mission slip would collapse the narrative and the financing window, and the equity (already a squeeze artifact) would round-trip the entire May rally.
• Single scenario that permanently impairs: a Vigoride mission failure (loss of vehicle / customer payloads). It would simultaneously destroy the technology-credibility thesis, the government-customer pipeline, and the ability to raise equity — for a 35-person, equity-funded company, that is terminal. Plausibility: non-trivial (1 of ~4 missions has already materially under-delivered).

Management Questions (ordered by information value)

1. At your current ~$23M+ annual operating burn, exactly how many revenue-generating missions does the present ~$76M cash fund, and what is the burn rate with a normal Vigoride mission cadence baked in?
2. What is the contracted, funded backlog in dollars (not "inbound inquiries") that converts to revenue in the next eight quarters — and what share is firm vs. optional?
3. The $10M FY2026 revenue guide: how much is already under signed contract today, and how much depends on missions not yet manifested or funded?
4. With the new $75M ATM stacked on the $50M just used, what is your expected share-count trajectory over the next two years, and at what point would you consider a third reverse split?
5. What were the quantified results of Vigoride 7's autonomous RPO and in-space-assembly demonstrations — did the multispectral RPO sensor suite and the NASA formation-flying objectives meet their primary success criteria?
6. Given Impulse Space, D-Orbit, and Astroscale are better-capitalized on the same missions, what specifically wins you a contract over them beyond price — and are you winning on price (i.e. below cost)?
7. How dependent is your U.S.-government revenue on specific SpaceWERX/AFRL/NASA line items that could be cut, and what is the concentration of your top customer?
8. What is the unit economics of a single Vigoride hosted-payload mission today — revenue, launch cost, integration cost, and gross margin per mission?
9. How transferable is the company's government-access advantage if John Rood were to depart — is the relationship/clearance moat institutional or personal?
10. What is the realistic timeline and incremental capital required to make OSVs reusable (the stated cost-down lever), and is that capital in the current plan?
11. What is the status and expected cost of the remaining ANV insurance-coverage matter and any residual fraud-derived derivative litigation?
12. Of the $76M cash, how much is restricted, and what are the encumbrances?
13. The ELOC pre-funded warrants and multiple warrant tranches: what is the maximum incremental share issuance from full exercise of all outstanding warrants/convertibles?
14. What gross-margin profile do you target at scale, and what annual revenue run-rate produces operating breakeven?
15. What is your honest assessment of the probability that a single mission failure would impair the company's ability to raise capital — and what is the contingency?

---